相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial
Christiane Maria Prado Jeronimo et al.
CLINICAL INFECTIOUS DISEASES (2021)
Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
Dong Huang et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: What is the connection?
Brittany Woodby et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2021)
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action
Hassan Yousefi et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection
Jin Wei et al.
CELL (2021)
COVID-19: Discovery, diagnostics and drug development
Tarik Asselah et al.
JOURNAL OF HEPATOLOGY (2021)
COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity
Marie Kroemer et al.
JOURNAL OF INFECTION (2021)
Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences
M. Shaminur Rahman et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives
Muhammad Saqib Sohail et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike 52 Subunit
Mahmoud Kandeel et al.
BIOMOLECULES & THERAPEUTICS (2021)
Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity
Erik Volz et al.
CELL (2021)
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Drew Weissman et al.
CELL HOST & MICROBE (2021)
Functional and druggability analysis of the SARS-CoV-2 proteome
Claudio N. Cavasotto et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial
Robert L. Gottlieb et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis
Bryan A. Johnson et al.
NATURE (2021)
Evolution of antibody immunity to SARS-CoV-2
Christian Gaebler et al.
NATURE (2021)
Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results
NEW ENGLAND JOURNAL OF MEDICINE (2021)
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
D. M. Weinreich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
NEW ENGLAND JOURNAL OF MEDICINE (2021)
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Peter Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Tyler N. Starr et al.
SCIENCE (2021)
Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors
Jonathan M. O. Rawson et al.
VIRUSES-BASEL (2021)
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
Zhiqiang Ku et al.
NATURE COMMUNICATIONS (2021)
Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
Julian Breidenbach et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Piyada Supasa et al.
CELL (2021)
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Daming Zhou et al.
CELL (2021)
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Xiaoying Shen et al.
CELL HOST & MICROBE (2021)
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
Gabriele Cerutti et al.
CELL HOST & MICROBE (2021)
Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication
Pruthvi Gowda et al.
CYTOKINE (2021)
High Mobility Group Box 1 Release by Cholangiocytes Governs Biliary Atresia Pathogenesis and Correlates With Increases in Afflicted Infants
Sujit K. Mohanty et al.
HEPATOLOGY (2021)
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Przemyslaw J. Kotyla et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Akt-independent effects of triciribine on ACE2 expression in human lung epithelial cells: Potential benefits in restricting SARS-CoV2 infection
Mir S. Adil et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2021)
S-Variant SARS-CoV-2 Lineage B1.1.7 Is Associated With Significantly Higher Viral Load in Samples Tested by TaqPath Polymerase Chain Reaction
Michael Kidd et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Importation of SARS-CoV-2 Variant B.1.1.7 in Pakistan
Massab Umair et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey et al.
LANCET (2021)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov et al.
LANCET (2021)
Sputnik V COVID-19 vaccine candidate appears safe and effective Comment
Ian Jones et al.
LANCET (2021)
NOVAVAX OFFERS FIRST EVIDENCE THAT COVID VACCINES PROTECT PEOPLE AGAINST VARIANTS
Ewen Callaway et al.
NATURE (2021)
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Pengfei Wang et al.
NATURE (2021)
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Zijun Wang et al.
NATURE (2021)
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer et al.
NATURE MEDICINE (2021)
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
Xuping Xie et al.
NATURE MEDICINE (2021)
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
Alexander Muik et al.
SCIENCE (2021)
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
Laurence Chu et al.
VACCINE (2021)
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
Jerzy Osipiuk et al.
NATURE COMMUNICATIONS (2021)
Maximum incubation period for COVID-19 infection: Do we need to rethink the 14-day quarantine policy?
Boris Bikbov et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2021)
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2021)
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
Matthew McCallum et al.
CELL (2021)
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Markus Hoffmann et al.
CELL (2021)
Antibody evasion by the P.1 strain of SARS-CoV-2
Wanwisa Dejnirattisai et al.
CELL (2021)
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP
Laura Solforosi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Katherine R. W. Emary et al.
LANCET (2021)
D936Y and Other Mutations in the Fusion Core of the SARS-CoV-2 Spike Protein Heptad Repeat 1: Frequency, Geographical Distribution, and Structural Effect
Romina Oliva et al.
MOLECULES (2021)
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Precision therapeutic targets for COVID-19
Zachary A. Krumm et al.
VIROLOGY JOURNAL (2021)
Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19
Meehyun Ko et al.
VIRUSES-BASEL (2021)
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
Yunlong Cao et al.
CELL RESEARCH (2021)
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Satoshi Ikegame et al.
NATURE COMMUNICATIONS (2021)
Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2
Baoying Huang et al.
LANCET MICROBE (2021)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Danuta M. Skowronski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Miao-Miao Zhao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Mutational insights into the envelope protein of SARS-CoV-2
M. Shaminur Rahman et al.
GENE REPORTS (2021)
Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil, December 2020
Ingra Morales Claro et al.
EMERGING INFECTIOUS DISEASES (2021)
The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design
Danielle C. Groves et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Neutralizing Antibody LY-CoV555 for Outpatient Covid-19
Arturo Casadevall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response
Yu-Zhi Fu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45-Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike Protein Activates the Nlrp3 Inflammasome
Mariusz Z. Ratajczak et al.
STEM CELL REVIEWS AND REPORTS (2021)
Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study
Yaseen M. Arabi et al.
CLINICAL INFECTIOUS DISEASES (2020)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
Shuai Xia et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics
David Gurwitz
DRUG DEVELOPMENT RESEARCH (2020)
Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent
Peter Serfozo et al.
HYPERTENSION (2020)
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
Dawei Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
Linlin Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
Roujian Lu et al.
LANCET (2020)
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen et al.
LANCET (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou et al.
NATURE (2020)
Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany
Camilla Rothe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Daniel Wrapp et al.
SCIENCE (2020)
Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials
Hilary S. Whitworth et al.
VACCINE (2020)
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Canrong Wu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)
Christian Schoergenhofer et al.
ANNALS OF INTERNAL MEDICINE (2020)
The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade
B. Coutard et al.
ANTIVIRAL RESEARCH (2020)
Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2
Sairaj Satarker et al.
ARCHIVES OF MEDICAL RESEARCH (2020)
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
Paola Toniati et al.
AUTOIMMUNITY REVIEWS (2020)
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
Steven P. Treon et al.
BLOOD (2020)
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
Vanessa Monteil et al.
CELL (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
Shuai Xia et al.
CELL RESEARCH (2020)
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
Wanbo Tai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
Wen Zhang et al.
CLINICAL IMMUNOLOGY (2020)
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Juanjuan Zhao et al.
CLINICAL INFECTIOUS DISEASES (2020)
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Chuan Qin et al.
CLINICAL INFECTIOUS DISEASES (2020)
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
Daniel Batlle et al.
CLINICAL SCIENCE (2020)
High Prevalence of Concurrent Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2: Early Experience From California
George Cholankeril et al.
GASTROENTEROLOGY (2020)
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Eli S. Rosenberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
COVID-19 and African Americans
Clyde W. Yancy
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Yang Cao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
A global treatments for coronaviruses including COVID-19
Bahman Yousefi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
Shutoku Matsuyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
Lisi Deng et al.
JOURNAL OF INFECTION (2020)
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
Yan Gao et al.
SCIENCE (2020)
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
Linlin Zhang et al.
SCIENCE (2020)
Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)
Ruiyun Li et al.
SCIENCE (2020)
The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections
Farhana Musarrat et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome
Christian A. Devaux et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2020)
Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins
Suhas Srinivasan et al.
VIRUSES-BASEL (2020)
A human monoclonal antibody blocking SARS-CoV-2 infection
Chunyan Wang et al.
NATURE COMMUNICATIONS (2020)
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity
Yuanmei Zhu et al.
JOURNAL OF VIROLOGY (2020)
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Ivan Fan-Ngai Hung et al.
LANCET (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Lei Fang et al.
LANCET RESPIRATORY MEDICINE (2020)
Interferon-α2b Treatment for COVID-19
Qiong Zhou et al.
FRONTIERS IN IMMUNOLOGY (2020)
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Bo Diao et al.
FRONTIERS IN IMMUNOLOGY (2020)
Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection
Zou Xin et al.
FRONTIERS OF MEDICINE (2020)
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)
Neil Mehta et al.
JAMA CARDIOLOGY (2020)
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
Fernanda Arnaldez et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Bin Ju et al.
NATURE (2020)
Hopes rise for coronavirus drug remdesivir
Heidi Ledford
NATURE (2020)
Structural basis of receptor recognition by SARS-CoV-2
Jian Shang et al.
NATURE (2020)
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin et al.
NATURE (2020)
Antibody responses to SARS-CoV-2 in patients with COVID-19
Quan-Xin Long et al.
NATURE MEDICINE (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Joshua Geleris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants
Muhammad Tahir ul Qamar et al.
JOURNAL OF PHARMACEUTICAL ANALYSIS (2020)
Molecular immune pathogenesis and diagnosis of COVID-19
Xiaowei Li et al.
JOURNAL OF PHARMACEUTICAL ANALYSIS (2020)
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
Tianxiao Liu et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients
Amr H. Sawalha et al.
CLINICAL IMMUNOLOGY (2020)
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Emanuel Della-Torre et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy
Jameel M. Inal
CLINICAL SCIENCE (2020)
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19
Effat Davoudi-Monfared et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Coronavirus membrane fusion mechanism offers a potential target for antiviral development
Tiffany Tang et al.
ANTIVIRAL RESEARCH (2020)
Proteasome activator PA28γ-dependent degradation of coronavirus disease (COVID-19) nucleocapsid protein
Haiyang Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Host-membrane interacting interface of the SARS coronavirus envelope protein: Immense functional potential of C-terminal domain
Shruti Mukherjee et al.
BIOPHYSICAL CHEMISTRY (2020)
A proposed role for the SARS-CoV-2 nucleocapsid protein in the formation and regulation of biomolecular condensates
Sean M. Cascarina et al.
FASEB JOURNAL (2020)
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
Hui Wang et al.
CELL (2020)
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells
Yunlong Cao et al.
CELL (2020)
Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients
Liting Chen et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Management of epigenomic networks entailed in coronavirus infections and COVID-19
Ranim El Baba et al.
CLINICAL EPIGENETICS (2020)
Tocilizumab for severe COVID-19: a systematic review and meta-analysis
Shao-Huan Lan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials
Shengli Xia et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
Eric Lawitz et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
Lakshmanane Premkumar et al.
SCIENCE IMMUNOLOGY (2020)
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Mark Roschewski et al.
SCIENCE IMMUNOLOGY (2020)
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
Yohei Doi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule
Alexis Werion et al.
KIDNEY INTERNATIONAL (2020)
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Feng-Cai Zhu et al.
LANCET (2020)
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
Carolyn Rydyznski Moderbacher et al.
CELL (2020)
Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19
Ramarao Poduri et al.
CELLULAR SIGNALLING (2020)
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
Donghyuk Shin et al.
NATURE (2020)
STEROID IS FIRST DRUG SHOWN TO PREVENT DEATHS FROM COVID-19
Heidi Ledford
NATURE (2020)
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Davide F. Robbiani et al.
NATURE (2020)
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Seth J. Zost et al.
NATURE MEDICINE (2020)
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
A. B. Cavalcanti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Structural insight into the role of novel SARS-CoV-2 E protein: A potential target for vaccine development and other therapeutic strategies
Manish Sarkar et al.
PLOS ONE (2020)
Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2
Theresa Klemm et al.
EMBO JOURNAL (2020)
Innate immune evasion bySARS-CoV-2: Comparison withSARS-CoV
Abdellatif Bouayad
REVIEWS IN MEDICAL VIROLOGY (2020)
Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients
Alessio Mazzoni et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2020)
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Xiangyang Chi et al.
SCIENCE (2020)
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
Alina Baum et al.
SCIENCE (2020)
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Johanna Hansen et al.
SCIENCE (2020)
The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner
Mizuki Yamamoto et al.
VIRUSES-BASEL (2020)
SARS-CoV-2 multifaceted interaction with the human host. PartII: Innate immunity response, immunopathology, and epigenetics
Tasnim H. Beacon et al.
IUBMB LIFE (2020)
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial
Pierre-Francois Dequin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial
Bruno M. Tomazini et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Racial/Ethnic Variation in Nasal Gene Expression of Transmembrane Serine Protease 2 (TMPRSS2)
Supinda Bunyavanich et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial
Derek C. Angus et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter W. Horby et al.
LANCET (2020)
Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination
Ariane Sternberg et al.
LIFE SCIENCES (2020)
Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147)
Ahmet Ozer Sehirli et al.
MOLECULAR BIOLOGY REPORTS (2020)
A leading coronavirus vaccine trial is on hold: scientists react
Nicky Phillips et al.
NATURE (2020)
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takehiro Takahashi et al.
NATURE (2020)
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Peter Horby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?
Christian Bailly et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Comparing the binding properties of peptides mimicking the Envelope protein ofSARS-CoVandSARS-CoV-2 to thePDZdomain of the tight junction-associatedPALS1protein
Angelo Toto et al.
PROTEIN SCIENCE (2020)
Mechanisms of SARS-CoV-2 Transmission and Pathogenesis
Andrew G. Harrison et al.
TRENDS IN IMMUNOLOGY (2020)
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial
Ricardo Palacios et al.
TRIALS (2020)
Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease
M. Nazmul Hoque et al.
PEERJ (2020)
Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
Marzieh Nojomi et al.
BMC INFECTIOUS DISEASES (2020)
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
Xiancai Ma et al.
IMMUNITY (2020)
Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics
Caio P. Gomes et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development
Mei-Yue Wang et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
Lymphocyte Changes in Severe COVID-19: Delayed Over-Activation of STING?
Jean-Marie Berthelot et al.
FRONTIERS IN IMMUNOLOGY (2020)
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
Ke Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
HMGB1 as a potential biomarker and therapeutic target for severe COVID-19
Ruochan Chen et al.
HELIYON (2020)
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L
Michael Dominic Sacco et al.
SCIENCE ADVANCES (2020)
Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers
Venkata S. Mandala et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)
Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor Therapeutic Implications
Anne M. Davidson et al.
HYPERTENSION (2020)
Anakinra for severe forms of COVID-19: a cohort study
Thomas Huet et al.
LANCET RHEUMATOLOGY (2020)
A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells
Yiliang Wang et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2020)
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Mehul S. Suthar et al.
CELL REPORTS MEDICINE (2020)
The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
Shuai Xia et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome
Luke Adam Monteagudo et al.
ACR OPEN RHEUMATOLOGY (2020)
The trinity of COVID-19: immunity, inflammation and intervention
Matthew Zirui Tay et al.
NATURE REVIEWS IMMUNOLOGY (2020)
CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
Henning Ulrich et al.
STEM CELL REVIEWS AND REPORTS (2020)
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Liying Dong et al.
DRUG DISCOVERIES AND THERAPEUTICS (2020)
Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries
Awadhesh Kumar Singh et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)
SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists
Chun-Kit Yuen et al.
EMERGING MICROBES & INFECTIONS (2020)
Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity
Yuanmei Zhu et al.
JOURNAL OF VIROLOGY (2019)
Interferons α and β in cancer: therapeutic opportunities from new insights
Ernest C. Borden
NATURE REVIEWS DRUG DISCOVERY (2019)
Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques
Huihui Chong et al.
PLOS PATHOGENS (2019)
Coronavirus envelope protein: current knowledge
Dewald Schoeman et al.
VIROLOGY JOURNAL (2019)
Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
Robert N. Kirchdoerfer et al.
NATURE COMMUNICATIONS (2019)
Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling
Yam Nath Paudel et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Michael D. Howell et al.
FRONTIERS IN IMMUNOLOGY (2019)
TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection
Naoko Iwata-Yoshikawa et al.
JOURNAL OF VIROLOGY (2019)
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
Iain B. McInnes et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
Yaseen M. Arabi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis
Yvette N. Lamb et al.
DRUGS (2018)
Anakinra for the treatment of rheumatoid arthritis: a safety evaluation
Julio Ramirez et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus
Yuanmei Zhu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
Mitochondria: Central Organelles for Melatonin's Antioxidant and Anti-Aging Actions
Russel J. Reiter et al.
MOLECULES (2018)
THE ACE2/ANGIOTENSIN-(1-7)/MAS AXIS OF THE RENIN-ANGIOTENSIN SYSTEM: FOCUS ON ANGIOTENSIN-(1-7)
Robson Augusto Souza Santos et al.
PHYSIOLOGICAL REVIEWS (2018)
Inhibition of NF-κB Signaling Pathway by Resveratrol Improves Spinal Cord Injury
Luyao Xu et al.
FRONTIERS IN NEUROSCIENCE (2018)
Cathepsin B and L inhibitors: a patent review (2010-present)
Yu-Yao Li et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Jesper Pallesen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
Rudragouda Channappanavar et al.
SEMINARS IN IMMUNOPATHOLOGY (2017)
The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy
Janina Bruening et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Origin and Evolution of RNA-Dependent RNA Polymerase
Savio T. de Farias et al.
FRONTIERS IN GENETICS (2017)
Tofacitinib: A Review in Rheumatoid Arthritis
Sohita Dhillon
DRUGS (2017)
Tocilizumab: A Review in Rheumatoid Arthritis
Lesley J. Scott
DRUGS (2017)
Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies
Seema Patel et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome
Akram Khan et al.
CRITICAL CARE (2017)
Autophagy induced by DAMPs facilitates the inflammation response in lungs undergoing ischemia-reperfusion injury through promoting TRAF6 ubiquitination
Xingguang Liu et al.
CELL DEATH AND DIFFERENTIATION (2017)
Effective inhibition of MERS-CoV infection by resveratrol
Shih-Chao Lin et al.
BMC INFECTIOUS DISEASES (2017)
Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases
Md Abdul Alim Al-Bari
PHARMACOLOGY RESEARCH & PERSPECTIVES (2017)
CD147 promotes IKK/I kappa B/NF-kappa B pathway to resist TNF-induced apoptosis in rheumatoid arthritis synovial fibroblasts
Yue Zhai et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay
Mizuki Yamamoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression
Douglas E. Linn et al.
CANCER RESEARCH (2016)
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial
Bita Shakoory et al.
CRITICAL CARE MEDICINE (2016)
Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer
Alexandra C. Walls et al.
NATURE (2016)
Pre-fusion structure of a human coronavirus spike protein
Robert N. Kirchdoerfer et al.
NATURE (2016)
Resveratrol Protects against TNF-α-Induced Injury in Human Umbilical Endothelial Cells through Promoting Sirtuin-1-Induced Repression of NF-KB and p38 MAPK
Wei Pan et al.
PLOS ONE (2016)
Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism
Jung-Eun Park et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The Membrane Protein of Severe Acute Respiratory Syndrome Coronavirus Functions as a Novel Cytosolic Pathogen-Associated Molecular Pattern To Promote Beta Interferon Induction via a Toll-Like-Receptor-Related TRAF3-Independent Mechanism
Yi Wang et al.
MBIO (2016)
Ebola virus dynamics in mice treated with favipiravir
Vincent Madelain et al.
ANTIVIRAL RESEARCH (2015)
A Mutant H3N2 Influenza Virus Uses an Alternative Activation Mechanism in TMPRSS2 Knockout Mice by Loss of an Oligosaccharide in the Hemagglutinin Stalk Region
Kouji Sakai et al.
JOURNAL OF VIROLOGY (2015)
Favipiravir for children with Ebola
Naim Bouazza et al.
LANCET (2015)
Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse
Yan YiWu et al.
SCIENCE CHINA-LIFE SCIENCES (2015)
Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
Jean Kaoru Millet et al.
VIRUS RESEARCH (2015)
Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
Adriaan H. de Wilde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
Lisa Oestereich et al.
ANTIVIRAL RESEARCH (2014)
Arbidol as a broad-spectrum antiviral: An update
Julie Blaising et al.
ANTIVIRAL RESEARCH (2014)
The SARS-coronavirus membrane protein induces apoptosis via interfering with PDK1-PKB/Akt signalling
Ho Tsoi et al.
BIOCHEMICAL JOURNAL (2014)
]Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis
K. Migita et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study
Jaffar A. Al-Tawfiq et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2014)
Crystal Structure of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Papain-like Protease Bound to Ubiquitin Facilitates Targeted Disruption of Deubiquitinating Activity to Demonstrate Its Role in Innate Immune Suppression
Ben A. Bailey-Elkin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein
Adeline Heurich et al.
JOURNAL OF VIROLOGY (2014)
Animal Model of Respiratory Syncytial Virus: CD8+ T Cells Cause a Cytokine Storm That Is Chemically Tractable by Sphingosine-1-Phosphate 1 Receptor Agonist Therapy
Kevin B. Walsh et al.
JOURNAL OF VIROLOGY (2014)
The Host Protease TMPRSS2 Plays a Major Role in In Vivo Replication of Emerging H7N9 and Seasonal Influenza Viruses
Kouji Sakai et al.
JOURNAL OF VIROLOGY (2014)
Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis-Related Disorders
Rami A. Al-Horani et al.
MEDICINAL RESEARCH REVIEWS (2014)
Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein
Jean Kaoru Millet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Pathogenic Influenza Viruses and Coronaviruses Utilize Similar and Contrasting Approaches To Control Interferon-Stimulated Gene Responses
Vineet D. Menachery et al.
MBIO (2014)
Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients
Fengming Huang et al.
NATURE COMMUNICATIONS (2014)
The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis
Jared M. Lucas et al.
CANCER DISCOVERY (2014)
A comprehensive collection of systems biology data characterizing the host response to viral infection
Brian D. Aevermann et al.
SCIENTIFIC DATA (2014)
Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects
Manuel Haschke et al.
CLINICAL PHARMACOKINETICS (2013)
Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2
Kazuya Shirato et al.
JOURNAL OF VIROLOGY (2013)
TMPRSS2 Activates the Human Coronavirus 229E for Cathepsin-Independent Host Cell Entry and Is Expressed in Viral Target Cells in the Respiratory Epithelium
Stephanie Bertram et al.
JOURNAL OF VIROLOGY (2013)
The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing Antibodies
Stefanie Gierer et al.
JOURNAL OF VIROLOGY (2013)
Identifying SARS-CoV Membrane Protein Amino Acid Residues Linked to Virus-Like Particle Assembly
Ying-Tzu Tseng et al.
PLOS ONE (2013)
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Lijun Sun et al.
SCIENCE (2013)
Role of Human Hypoxanthine Guanine Phosphoribosyltransferase in Activation of the Antiviral Agent T-705 (Favipiravir)
Lieve Naesens et al.
MOLECULAR PHARMACOLOGY (2013)
Population-Based Study of Statins, Angiotensin II Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors on Pneumonia-Related Outcomes
Eric M. Mortensen et al.
CLINICAL INFECTIOUS DISEASES (2012)
Critical role for calcium mobilization in activation of the NLRP3 inflammasome
Tomohiko Murakami et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Ready, Set, Fuse! The Coronavirus Spike Protein and Acquisition of Fusion Competence
Taylor Heald-Sargent et al.
VIRUSES-BASEL (2012)
Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum
Cecile Crosnier et al.
NATURE (2011)
Heparin Enhances Serpin Inhibition of the Cysteine Protease Cathepsin L
Wayne J. Higgins et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The Membrane Protein of Severe Acute Respiratory Syndrome Coronavirus Acts as a Dominant Immunogen Revealed by a Clustering Region of Novel Functionally and Structurally Defined Cytotoxic T-Lymphocyte Epitopes
Jun Liu et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2
Shutoku Matsuyama et al.
JOURNAL OF VIROLOGY (2010)
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Taro Kawai et al.
NATURE IMMUNOLOGY (2010)
Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease Ubiquitin-Like Domain and Catalytic Domain Regulate Antagonism of IRF3 and NF-κB Signaling
Matthew Frieman et al.
JOURNAL OF VIROLOGY (2009)
Characterization of a Highly Conserved Domain within the Severe Acute Respiratory Syndrome Coronavirus Spike Protein S2 Domain with Characteristics of a Viral Fusion Peptide
Ikenna G. Madu et al.
JOURNAL OF VIROLOGY (2009)
Coronaviruses post-SARS: update on replication and pathogenesis
Stanley Perlman et al.
NATURE REVIEWS MICROBIOLOGY (2009)
Pathogen recognition by innate immunity and its signaling
Shizuo Akira
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2009)
Structure and Inhibition of the SARS Coronavirus Envelope Protein Ion Channel
Konstantin Pervushin et al.
PLOS PATHOGENS (2009)
Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus
Santhana G. Devaraj et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium
Eva Böttcher et al.
JOURNAL OF VIROLOGY (2006)
SARS: Systematic review of treatment effects
Lauren J. Stockman et al.
PLOS MEDICINE (2006)
Ribavirin-induced anemia: Mechanisms, risk factors and related targets for future research
Stefan Russmann et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Tumor necrosis factor-α convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)
DW Lambert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
K Kuba et al.
NATURE MEDICINE (2005)
Multiple organ infection and the pathogenesis of SARS
J Gu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
CM Ferrario et al.
CIRCULATION (2005)
Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan
WJ Shieh et al.
HUMAN PATHOLOGY (2005)
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Martin J. Vincent et al.
VIROLOGY JOURNAL (2005)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
CM Chu et al.
THORAX (2004)
Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity
BH Harcourt et al.
JOURNAL OF VIROLOGY (2004)
Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
I Hamming et al.
JOURNAL OF PATHOLOGY (2004)
Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways
YQ Ding et al.
JOURNAL OF PATHOLOGY (2004)
Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice - A renoprotective combination?
MH Ye et al.
HYPERTENSION (2004)
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
WH Li et al.
NATURE (2003)
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
J Cinatl et al.
LANCET (2003)
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
CM Booth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Priming the nucleosome: a role for HMGB proteins?
AA Travers
EMBO REPORTS (2003)
The palm subdomain-based active site is internally permuted in viral RNA-dependent RNA polymerases of an ancient lineage
AE Gorbalenya et al.
JOURNAL OF MOLECULAR BIOLOGY (2002)
Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain
K Anand et al.
EMBO JOURNAL (2002)
分享论文
